» Articles » PMID: 15229465

Nicotine Metabolite Ratio As an Index of Cytochrome P450 2A6 Metabolic Activity

Overview
Publisher Wiley
Specialty Pharmacology
Date 2004 Jul 2
PMID 15229465
Citations 244
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nicotine and a variety of other drugs and toxins are metabolized by cytochrome P450 (CYP) 2A6. Our objective was to evaluate the use of oral nicotine with measurement of the trans-3'-hydroxycotinine (3HC)/cotinine (COT) metabolite ratio as a noninvasive probe of CYP2A6 activity.

Methods: Sixty-two healthy volunteers received an oral solution of deuterium-labeled nicotine (2 mg) and its metabolite cotinine (10 mg). Plasma nicotine and plasma and saliva cotinine and 3HC concentrations were measured over time.

Results: The 3HC/COT ratio derived from deuterium-labeled cotinine, measured in either plasma (2-8 hours after administration) or saliva (at 6 hours), was strongly correlated with the oral clearance of nicotine (r = 0.76-0.83, depending on the time of measurement). The 6-hour 3HC/COT ratio from nicotine derived from tobacco in 14 smokers was highly correlated with the ratio derived from deuterium-labeled nicotine (r = 0.88) and was also highly correlated with the oral clearance of nicotine (r = 0.90). Two subjects homozygous for inactive CYP2A6 alleles produced no 3HC, confirming the specificity of the metabolite ratio. The 3HC/COT ratio was also highly correlated with the clearance and half-life of cotinine, consistent with the fact that cotinine is also primarily metabolized by CYP2A6.

Conclusions: The 3HC/COT ratio derived from nicotine either administered as a probe drug or from tobacco use, measured in either plasma or saliva, is highly correlated with the oral clearance of nicotine. The ratio appears to be a useful noninvasive marker of the rate of nicotine metabolism (which is important in studying nicotine addiction and smoking behavior), as well as a general marker of CYP2A6 activity (which is important in studying drug and toxin metabolism).

Citing Articles

Plasma nicotine and its metabolite as biomarkers of tobacco exposure and their relevance to pulmonary nodule.

Wang N, Xiao W, Tang Q, Hu W, Wang S, Zhang Z Biomark Med. 2024; 18(23):1061-1073.

PMID: 39564794 PMC: 11633419. DOI: 10.1080/17520363.2024.2422809.


Urine levels of nicotine and its metabolites in young population exposed to second-hand smoke in nightclubs: a pilot study.

Zecic A, Vazdar B, Sliskovic L, Sutlovic D Arh Hig Rada Toksikol. 2024; 75(3):211-216.

PMID: 39369327 PMC: 11456220. DOI: 10.2478/aiht-2024-75-3846.


The hidden impact: the rate of nicotine metabolism and kidney health.

Wang X, Su S Front Endocrinol (Lausanne). 2024; 15:1424068.

PMID: 39355620 PMC: 11442274. DOI: 10.3389/fendo.2024.1424068.


Implementing a Metabolism-informed approach for smoking cessation in an Alaska Tribal health system: study protocol for a single-arm implementation pilot trial.

Jansen K, Tranby B, Shane A, Takeno T, Chadwick K, Sinicrope P Arch Public Health. 2024; 82(1):129.

PMID: 39175017 PMC: 11340097. DOI: 10.1186/s13690-024-01365-7.


PharmVar GeneFocus: CYP2A6.

Langlois A, Chenoweth M, Twesigomwe D, Scantamburlo G, Whirl-Carrillo M, Sangkuhl K Clin Pharmacol Ther. 2024; 116(4):948-962.

PMID: 39051767 PMC: 11452280. DOI: 10.1002/cpt.3387.